Berberine Evaluated for Liver Fat

Six-month randomized trial finds no reduction in visceral or hepatic fat in patients with obesity and MASLD

1

Berberine did not reduce visceral adipose tissue or liver fat in patients with obesity and metabolic dysfunction-associated steatotic liver disease.
2

The study involved 337 patients, randomly assigned to receive either 1 g of oral berberine daily or a placebo for 6 months.
3

No significant differences were found between the berberine and placebo groups in primary outcomes after 6 months.
4

Berberine was associated with reductions in low-density lipoprotein cholesterol and high-sensitivity C-reactive protein.
5

The trial reported an excellent safety profile for berberine, with similar adverse event rates between treatment and placebo groups.

1